Literature DB >> 25062500

HDAC inhibitor-mediated beta-cell protection against cytokine-induced toxicity is STAT1 Tyr701 phosphorylation independent.

Mattias S Dahllöf1, Dan P Christensen, Mette Harving, Bridget K Wagner, Thomas Mandrup-Poulsen, Morten Lundh.   

Abstract

Histone deacetylase (HDAC) inhibition protects pancreatic beta-cells against apoptosis induced by the combination of the proinflammatory cytokines interleukin (IL)-1β and interferon (IFN)-γ. Decreased expression of cell damage-related genes is observed on the transcriptional level upon HDAC inhibition using either IL-1β or IFN-γ alone. Whereas HDAC inhibition has been shown to regulate NFκB-activity, related primarily to IL-1β signaling, it is unknown whether the inhibition of HDACs affect IFN-γ signaling in beta-cells. Further, in non-beta-cells, there is a dispute whether HDAC inhibition regulates IFN-γ signaling at the level of STAT1 Tyr701 phosphorylation. Using different small molecule HDAC inhibitors with varying class selectivity, INS-1E wild type and stable HDAC1-3 knockdown pancreatic INS-1 cell lines, we show that IFN-γ-induced Cxcl9 and iNos expression as well as Cxcl9 and GAS reporter activity were decreased by HDAC inhibition in a STAT1 Tyr701 phosphorylation-independent fashion. In fact, knockdown of HDAC1 increased IFN-γ-induced STAT1 phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25062500      PMCID: PMC4291159          DOI: 10.1089/jir.2014.0022

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  27 in total

1.  Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children.

Authors:  M Lundh; D P Christensen; M Damgaard Nielsen; S J Richardson; M S Dahllöf; T Skovgaard; J Berthelsen; C A Dinarello; A Stevenazzi; P Mascagni; L G Grunnet; N G Morgan; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2012-07-07       Impact factor: 10.122

Review 2.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

3.  Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines.

Authors:  M Lundh; D P Christensen; D N Rasmussen; P Mascagni; C A Dinarello; N Billestrup; L G Grunnet; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2010-09-28       Impact factor: 10.122

Review 4.  Cytokines and beta-cell biology: from concept to clinical translation.

Authors:  Marc Y Donath; Joachim Størling; Lukas A Berchtold; Nils Billestrup; Thomas Mandrup-Poulsen
Journal:  Endocr Rev       Date:  2007-11-29       Impact factor: 19.871

5.  Acetylation of Stat1 modulates NF-kappaB activity.

Authors:  Oliver H Krämer; Daniela Baus; Shirley K Knauer; Stefan Stein; Elke Jäger; Roland H Stauber; Manuel Grez; Edith Pfitzner; Thorsten Heinzel
Journal:  Genes Dev       Date:  2006-02-15       Impact factor: 11.361

6.  Synergistic expression of the CXCL10 gene in response to IL-1β and IFN-γ involves NF-κB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4.

Authors:  Susan J Burke; Matthew R Goff; Danhong Lu; David Proud; Michael D Karlstad; J Jason Collier
Journal:  J Immunol       Date:  2013-06-05       Impact factor: 5.422

7.  Histone deacetylase inhibitors block IFNγ-induced STAT1 phosphorylation.

Authors:  Torsten Ginter; Carolin Bier; Shirley K Knauer; Kalsoom Sughra; Dagmar Hildebrand; Tobias Münz; Theresa Liebe; Regine Heller; Andreas Henke; Roland H Stauber; Werner Reichardt; Johannes A Schmid; Katharina F Kubatzky; Thorsten Heinzel; Oliver H Krämer
Journal:  Cell Signal       Date:  2012-03-07       Impact factor: 4.315

Review 8.  Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling.

Authors:  Chilakamarti V Ramana; M Pilar Gil; Robert D Schreiber; George R Stark
Journal:  Trends Immunol       Date:  2002-02       Impact factor: 16.687

9.  Small-molecule inhibitors of cytokine-mediated STAT1 signal transduction in β-cells with improved aqueous solubility.

Authors:  Stephen S Scully; Alicia J Tang; Morten Lundh; Carrie M Mosher; Kedar M Perkins; Bridget K Wagner
Journal:  J Med Chem       Date:  2013-05-13       Impact factor: 7.446

10.  Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes.

Authors:  Zhibin Wang; Chongzhi Zang; Kairong Cui; Dustin E Schones; Artem Barski; Weiqun Peng; Keji Zhao
Journal:  Cell       Date:  2009-08-20       Impact factor: 41.582

View more
  5 in total

1.  Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice.

Authors:  Alix Besançon; Tania Goncalves; Fabrice Valette; Mattias S Dahllöf; Thomas Mandrup-Poulsen; Lucienne Chatenoud; Sylvaine You
Journal:  Diabetologia       Date:  2017-10-13       Impact factor: 10.122

Review 2.  Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases.

Authors:  Himavanth Reddy Gatla; Nethaji Muniraj; Prashanth Thevkar; Siddhartha Yavvari; Sahithi Sukhavasi; Monish Ram Makena
Journal:  Int J Mol Sci       Date:  2019-03-05       Impact factor: 5.923

3.  Gestation and breastfeeding in schistosomotic mice differentially alters the expression of histone deacetylases (HDACs) in adult offspring.

Authors:  Gabriela Calixto Ribeiro de Holanda; Fabrício Oliveira Souto; Maria da Conceição Silva; Virgínia Maria Barros de Lorena; Vlaudia Maria Assis Costa; Monica Camelo Pessôa de Azevedo Albuquerque; Valdênia Maria Oliveira de Souza; José Luiz de Lima Filho
Journal:  Mem Inst Oswaldo Cruz       Date:  2020-02-03       Impact factor: 2.743

4.  Intestinal Inflammation is Linked to Hypoacetylation of Histone 3 Lysine 27 and can be Reversed by Valproic Acid Treatment in Inflammatory Bowel Disease Patients.

Authors:  C Felice; A Lewis; S Iqbal; H Gordon; A Rigoni; M P Colombo; A Armuzzi; R Feakins; J O Lindsay; A Silver
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-11-21

Review 5.  The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.

Authors:  Saikat Dewanjee; Jayalakshmi Vallamkondu; Rajkumar Singh Kalra; Pratik Chakraborty; Moumita Gangopadhyay; Ranabir Sahu; Vijaykrishna Medala; Albin John; P Hemachandra Reddy; Vincenzo De Feo; Ramesh Kandimalla
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.